MELD

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 8, 2021
F1, Mortality, Safety, Hepatic encephalopathy, Ascites, Cirrhosis, Clinical trial, Eleazar Sukenik, Terminology, EMA, Liver, COVID-19, Overweight, Medication, Annual report, Forward-looking statement, Perception, Risk, Hebrew University of Jerusalem, Kinetics, ARMOR, Patient, NASH, SEC, Inflammation, Pharmacokinetics, Physician, Fibrosis, Time, MELD, FDA, Biopsy, Drug development, Pharmaceutical industry

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.

Key Points: 
  • Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.
  • We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.
  • Patients are randomized (1:1:1) into three groups with post-baseline liver biopsy being performed at 24 weeks, 48 weeks, or 72 weeks, respectively.

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Retrieved on: 
Monday, November 8, 2021
F1, Mortality, Safety, Hepatic encephalopathy, Ascites, Cirrhosis, Clinical trial, Eleazar Sukenik, Terminology, EMA, Liver, COVID-19, Multimedia, Overweight, Medication, Annual report, Forward-looking statement, Perception, Risk, Hebrew University of Jerusalem, Kinetics, ARMOR, Patient, NASH, SEC, Inflammation, Pharmacokinetics, Physician, Fibrosis, Time, MELD, FDA, Biopsy, Drug development, Pharmaceutical industry

-- Results are an early indication that higher dose of Aramchol could provide statistically and clinically meaningful effect on fibrosis in the double-blind placebo controlled regulatory part for submission of an NDA under Sub-part H--

Key Points: 
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.
  • We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.
  • Patients are randomized (1:1:1) into three groups with post-baseline liver biopsy being performed at 24 weeks, 48 weeks, or 72 weeks, respectively.
  • The primary histology-based endpoint is NASH resolution without worsening of fibrosis or fibrosis improvement without NASH worsening.

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Retrieved on: 
Monday, November 1, 2021
Safety, Fibrosis, Medication, Hebrew University of Jerusalem, Inflammation, Drug development, F1, Hepatic encephalopathy, MELD, Cirrhosis, Kinetics, EMA, Perception, Eleazar Sukenik, Patient, ARMOR, FDA, Terminology, Biopsy, SEC, Time, Annual report, Forward-looking statement, Risk, Clinical trial, Ascites, COVID-19, Overweight, Pharmacokinetics, Mortality, NASH, Liver, Physician, Pharmaceutical industry

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.

Key Points: 
  • Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.
  • We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.
  • Patients are randomized (1:1:1) into three groups with post-baseline liver biopsy being performed at 24 weeks, 48 weeks, or 72 weeks, respectively.

Tingo International Holdings, Inc. Announces Partnership with MELD

Retrieved on: 
Friday, October 1, 2021
Cardano, Decentralized finance, EUR, MELD, Environmental, social and corporate governance, Insurance, Hunger, Biophysical environment, Securities Act of 1933, Partnership, Review, Compliance, USD, Â, ESG, OTC, Solution, Sale, Food security, Intention, Corporate governance, OEM, Income, ADA, Financial technology, Social, Entrepreneurship, Farm, Fiat, Sustainable Development Goals, Female, OTC Markets Group, Gold, GSM, Non-fungible token, Securities Exchange Act of 1934, Ecosystem, United, SEC, GLOBE, Poverty, Security (finance), Cryptocurrency, Renewable energy, Mobile phone

LOS ANGELES, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Tingo International Holdings (Tingo), majority shareholder of Tingo Inc. (OTC: IWBB) , a unique agri-fintech company, announces a new partnership with MELD, an open-source, non-custodial liquidity protocol that securely lends and borrows both crypto and fiat currencies.

Key Points: 
  • LOS ANGELES, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Tingo International Holdings (Tingo), majority shareholder of Tingo Inc. (OTC: IWBB) , a unique agri-fintech company, announces a new partnership with MELD, an open-source, non-custodial liquidity protocol that securely lends and borrows both crypto and fiat currencies.
  • This important partnership between Tingo International Holdings and Meld is designed to deliver a highly efficient DeFi lending and borrowing protocol to customers in Africa.
  • Tingo believes that a high-efficiency, DeFi protocol like MELD can provide a great deal of value to Tingo customers, even with many transactions below USD$100.
  • Tingo International holdings is a majority shareholder in Tingo Inc (OTC Markets: IWBB), which owns 100% of Tingo Mobile PLC in Nigeria.

MELD Advertising Unveils New Brand, Website

Retrieved on: 
Monday, August 30, 2021
Wood, Advertising, Founder, Technology, Human, Ethics, MELD, Public relations

NEW YORK, Aug. 30, 2021 /PRNewswire/ --MELD Advertising, a leading full-service marketing agency, has announced the launch of its new branding, complete with a new logo and a refresh of its website.

Key Points: 
  • NEW YORK, Aug. 30, 2021 /PRNewswire/ --MELD Advertising, a leading full-service marketing agency, has announced the launch of its new branding, complete with a new logo and a refresh of its website.
  • The updated website has been introduced at meldadvertising.com and reflects the new brand identity, showcases MELD's work for its clients, details the agency's capabilities, and more.
  • The new logo, which can be seen throughout the new website, has a more colorful design that conveys a warmer, more confident tone.
  • As part of the brand refresh, MELD also has an updated value proposition: Inspiring trust by ensuring your success.